SCHEMBL16865709

SCHEMBL16865709

O=C(/N=[13C](/Nc1cc(F)cc(Cl)c1)Nc1cc(C(F)(F)F)[nH]n1)[13c]1[13cH][13cH][13cH][13c](Cl)[13cH]1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.65
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CCNA1 P78396 1/20 0.38
ALOX15 P16050 1/20 0.37
SLC6A9 P48067 1/20 0.36
SLC6A5 Q9Y345 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ACR P10323 1/20 0.35
RXFP1 Q9HBX9 1/20 0.34
RHOC P08134 1/20 0.34
RHOA P61586 1/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
MAPK14 Q16539 1/20 0.34
PLK4 O00444 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16794424 1.00 CYP2D6 (0.65) CYP2D6RAB9ANPC1CCNA2CDK2
SCHEMBL16794322 1.00 CYP2D6 (0.65) CYP2D6RAB9ANPC1CCNA2CDK2
Acetone SCHEMBL16794405 0.97 CYP2D6 (0.62) CYP2D6RAB9ANPC1CCNA2CDK2
Acetone SCHEMBL16794404 0.97 CYP2D6 (0.62) CYP2D6RAB9ANPC1CCNA2CDK2
SCHEMBL19135677 0.93 CYP2D6 (0.57) CYP2D6RAB9ANPC1CCNA2CDK2
SCHEMBL16794486 0.91 CYP2D6 (0.62) CYP2D6RAB9ANPC1CCNA2CDK2
SCHEMBL16794484 0.91 CYP2D6 (0.62) CYP2D6RAB9ANPC1CCNA2CDK2
SCHEMBL18162905 0.90 CYP2D6 (0.52) CYP2D6RAB9ANPC1CCNA2CDK2
SCHEMBL16811839 0.90 CYP2D6 (0.54) CYP2D6RAB9ANPC1CCNA2CDK2
SCHEMBL16860011 0.90 CYP2D6 (0.54) CYP2D6RAB9ANPC1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170354643-A1 TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-12-14 US disclosed
US-9266839-B2 Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2016-02-23 US disclosed
US-20150183745-A1 TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2015-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170354643-A1 TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5ME, ATP5F1D CYP2D6 2844/4885RAB9A 385/4885NPC1 1226/4885
US-20150183745-A1 TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5ME, ATP5F1D CYP2D6 2844/4885RAB9A 385/4885NPC1 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.